Immune Therapy Generates Promising Results in Hard-to-Treat Ankylosing Spondylitis
(WorldNews Business)

Embargo/Online Publication Date: 17:30 Hours ET, Saturday, October 20, 2018 [22.30 Hours UK Time (BST)/8:30 Hours Australian Eastern Daylight Time (AEDT), October 21] Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis (AS), a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab. The findings will be presented at the American College of Rheumatology`s annual meeting in Chicago (October 20-24, 2018) and simultaneously published in the ACR journal,Arthritis & Rheumatology. Approximately 30 to 40 percent of patients...